Bank Julius Baer & Co
BIB icon

Bank Julius Baer & Co’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bank Julius Baer & Co’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,000
Closed -$502K – 823
2021
Q1 		$502K Sell
6,000
-1
-0% -$94 ﹤0.01% 444
2020
Q4 		$518K Buy
6,001
+1
+0% +$77 ﹤0.01% 446
2020
Q3 		$421K Sell
6,000
-5,000
-45% -$355K ﹤0.01% 410
2020
Q2 		$798K Buy
11,000
+2,951
+37% +$188K 0.01% 301
2020
Q1 		$370K Buy
+8,049
New +$448K 0.01% 349

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UMC
United Maritime Capital New York $15.2M AUM 45.42% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Bank Julius Baer & Co's BIB Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2021, closing a stake of 6,000 shares — an estimated $502K sold.

Bank Julius Baer & Co first reported a position in BIB in Q1 2020 and held it in 5 quarters. The position peaked at $798K in Q2 2020. 36 funds tracked by Wall St. Rank hold BIB as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 6,000 ProShares Ultra NASDAQ Biotechnology shares in Q2 2021, an estimated $502K.
  • Bank Julius Baer & Co first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2020 and held it in 5 quarters.
  • Bank Julius Baer & Co's ProShares Ultra NASDAQ Biotechnology position peaked at $798K in Q2 2020.
  • 36 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.